Nardi, Antonio Egidio, Valenca, AM, Freire, Rafael C, Mochcovitch, Marina, Amrein, R, Sardinha, Aline A, Levitan, Michele N, Nascimento, Isabella, de-Melo-Neto, Valfrido Leao, King, Anna Lucia, e Silva, Adriana, Veras, Andre B, Pereira Dias, Gisele ORCID: https://orcid.org/0000-0001-7276-2010, Soares-Filho, Galvao, da Costa, Rafael Thomaz, Mezzasalma, MA, de Carvalho, Marcele Regine, de Cerqueira, Ana Claudia, Hallak, JE, Crippa, JA and Versiani, Marcio (2011) Psychopharmacotherapy of panic disorder: 8-week randomized trial with clonazepam and paroxetine. Brazilian Journal of Medical and Biological Research, 44. pp. 366-373. ISSN 0100-879X (Print), 1414-431X (Online) (doi:10.1590/S0100-879X2011007500020)

Preview

PDF (Publisher's PDF - Open Access) 23929 PEREIRA DIAS_Psychopharmacotherapy_of_Panic_Disorder_2011.pdf - Published Version Available under License Creative Commons Attribution Non-commercial. Download (661kB) | Preview

Abstract

The objective of the present randomized, open-label, naturalistic 8-week study was to compare the efficacy and safety of treat- ment with clonazepam (N = 63) and paroxetine (N = 57) in patients with panic disorder with or without agoraphobia. Efficacy assessment included number of panic attacks and clinician ratings of the global severity of panic disorders with the clinical global impression (CGI) improvement (CGI-I) and CGI severity (CGI-S) scales. Most patients were females (69.8 and 68.4% in the clonazepam and paroxetine groups, respectively) and age (mean ± SD) was 35.9 ± 9.6 years for the clonazepam group and 33.7 ± 8.8 years for the paroxetine group. Treatment with clonazepam versus paroxetine resulted in fewer weekly panic attacks at week 4 (0.1 vs 0.5, respectively; P < 0.01), and greater clinical improvements at week 8 (CGI-I: 1.6 vs 2.9; P = 0.04). Anxiety severity was significantly reduced with clonazepam versus paroxetine at weeks 1 and 2, with no difference in panic disorder severity. Patients treated with clonazepam had fewer adverse events than patients treated with paroxetine (73 vs 95%; P = 0.001). The most common adverse events were drowsiness/fatigue (57%), memory/concentration difficulties (24%), and sexual dysfunction (11%) in the clonazepam group and drowsiness/fatigue (81%), sexual dysfunction (70%), and nausea/vomiting (61%) in the paroxetine group. This naturalistic study confirms the efficacy and tolerability of clonazepam and paroxetine in the acute treatment of patients with panic disorder.

Item Type:	Article
Additional Information:	All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License.
Uncontrolled Keywords:	Paroxetine; Clonazepam; Panic disorder; Efficacy; Safety
Subjects:	B Philosophy. Psychology. Religion > BF Psychology
Last Modified:	03 Jul 2019 15:45
URI:	http://gala.gre.ac.uk/id/eprint/23929

Actions (login required)

View Item

Downloads